Phase I trial of interferon gamma retroviral vector administered intratumorally with multiple courses in patients with metastatic melanoma.
The purpose of this study was to determine the safety and antitumor activity of IFN-gamma retroviral vector in patients with advanced melanoma. Seventeen patients (9 single courses, 8 multiple courses) received a total of 363 intratumor injections of IFN-gamma retroviral vector (1 x 10(7) PFU/ml administered at 0.3, 0.5, and 1.0 ml per cohort). No grade III/IV adverse events were attributed to study medication. Replication-competent retrovirus was not detected in any of the 17 patients by polymerase chain reaction studies. Eight patients showed elevated anti-tumor antibody responses in comparison with baseline by ELISA. One of nine patients treated with a single course had an optimal response of stable disease, compared with eight of eight multiple-injected patients. Median survival of single-injected patients was 150 days, and patients who received multiple injections have still not achieved median survival duration, with four of eight still living (p = 0.0462, Wilcoxon; p = 0.0273, log rank). We conclude that intratumor injection of IFN-gamma is safe and well tolerated. Evidence of antitumor activity is suggested in patients with advanced malignancy that received multiple injections.
Nemunaitis
J
J
PRN Research, Inc., Dallas, TX 75246, USA. JJNemun@PRNINC.com
Fong
T
T
Burrows
F
F
Bruce
J
J
Peters
G
G
Ognoskie
N
N
Meyer
W
W
Wynne
D
D
Kerr
R
R
Pippen
J
J
Oldham
F
F
Ando
D
D
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000912:Antibodies, Neoplasm / Q000276:immunology; D000970:Antineoplastic Agents / Q000276:immunology / Q000627:therapeutic use*; D015331:Cohort Studies; D005260:Female; D015316:Genetic Therapy / Q000009:adverse effects / Q000379:methods*; D005822:Genetic Vectors; D006801:Humans; D007267:Injections; D007371:Interferon-gamma / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*; D008297:Male; D008545:Melanoma / Q000276:immunology / Q000473:pathology / Q000556:secondary* / Q000628:therapy*; D008875:Middle Aged; D008979:Moloney murine leukemia virus; D014407:Tumor Cells, Cultured
D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D007371:Interferon-gamma